The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?
Open accessAbstract
There is unequivocal evidence of an inverse association between plasma high-density lipoprotein (HDL) cholesterol concentrations and the risk of cardiovascular disease, a finding that has led to the hypothesis that HDL protects from atherosclerosis. This review details the experimental evidence for this "HDL hypothesis". In vitro studies suggest that HDL has a wide range of anti-atherogenic properties but validation of these functions in humans is absent to date. A significant number of animal studies and clinical trials support an atheroprotective role for HDL; however, most of these findings were obtained in the context of marked changes in other plasma lipids. Finally, genetic studies in humans have not provided convincing evidence that HDL genes modulate cardiovascular risk. Thus, despite a wealth of information on this intriguing lipoprotein, future research remains essential to prove the HDL hypothesis correct.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Research works printed but not linked: 183
- Barr, 1951, Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions, Am. J. Med., 11, 480, 10.1016/0002-9343(51)90183-0 · DOI · Paper page
- Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease: The Framingham study, Am. J. Med., 62, 707, 10.1016/0002-9343(77)90874-9 · DOI · Paper page
- 2008, Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials, BMJ., 336, 1121, 10.1136/bmj.39548.738368.BE · DOI · Paper page
- Hausenloy, 2008, Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels, Heart., 94, 706, 10.1136/hrt.2007.125401 · DOI
- Wild, 2008, Time to rethink high-density lipoprotein?, Heart., 94, 692, 10.1136/hrt.2007.126326 · DOI
- Hansel, 2006, One third of the variability in HDL-cholesterol level in a large dyslipidaemic population is predicted by age, sex and triglyceridaemia: The Paris La Pitie Study, Curr. Med. Res. Opin., 22, 1149, 10.1185/030079906X104821 · DOI
- Criqui, 1980, Cigarette smoking and plasma high-density lipoprotein cholesterol. The Lipid Research Clinics Program Prevalence Study, Circulation., 62, IV70
- Hulley, 1977, Plasma high-density lipoprotein cholesterol level. Influence of risk factor intervention, JAMA., 238, 2269, 10.1001/jama.1977.03280220037017 · DOI
- Gnasso, 1984, Acute influence of smoking on plasma lipoproteins, Klin. Wochenschr., 62, 36
- Kodama, 2007, Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis, Arch. Intern. Med., 167, 999, 10.1001/archinte.167.10.999 · DOI · Paper page
- Rashid, 2007, Effect of obesity on high-density lipoprotein metabolism, Obesity (Silver Spring)., 15, 2875, 10.1038/oby.2007.342 · DOI · Paper page
- Busetto, 2004, Short-term effects of weight loss on the cardiovascular risk factors in morbidly obese patients, Obesity (Silver Spring)., 12, 1256
- Lann, 2007, Insulin resistance as the underlying cause for the metabolic syndrome, Med. Clin. North Am., 91, 1063, 10.1016/j.mcna.2007.06.012 · DOI · Paper page
- Hayek, 1993, Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice, J. Clin. Invest., 92, 1143, 10.1172/JCI116683 · DOI
- Tai, 1999, Isolated low HDL cholesterol: an insulin-resistant state only in the presence of fasting hypertriglyceridemia, Diabetes., 48, 1088, 10.2337/diabetes.48.5.1088 · DOI
- van Leuven, 2008, Systemic inflammation as a risk factor for atherothrombosis, Rheumatology., 47, 3, 10.1093/rheumatology/kem202 · DOI · Paper page
- Khovidhunkit, 2000, Infection and inflammation-induced proatherogenic changes of lipoproteins, J. Infect. Dis., 181, S462, 10.1086/315611 · DOI · Paper page
- Heiss, 1980, Plasma high-density lipoprotein cholesterol and socioeconomic status. The Lipid Research Clinics Program Prevalence Study, Circulation., 62, IV108
- Sapolsky, 1987, Social subordinance in wild baboons is associated with suppressed high density lipoprotein-cholesterol concentrations: the possible role of chronic social stress, Endocrinology., 121, 1605, 10.1210/endo-121-5-1605 · DOI
- Kontush, 2006, Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis, Pharmacol. Rev., 58, 342, 10.1124/pr.58.3.1 · DOI · Paper page
- Fielding, 1982, Cholesterol transport between cells and body fluids. Role of plasma lipoproteins and the plasma cholesterol esterification system, Med. Clin. North Am., 66, 363, 10.1016/S0025-7125(16)31425-0 · doi:10.1016/s0025-7125(16)31425-0
- Groen, 2001, Hepatobiliary cholesterol transport is not impaired in Abca1-null mice lacking HDL, J. Clin. Invest., 108, 843, 10.1172/JCI200112473 · doi:10.1172/jci200112473
- Alam, 2001, Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice, J. Biol. Chem., 276, 15641, 10.1074/jbc.M010230200 · DOI
- deGoma, 2008, Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches, J. Am. Coll. Cardiol., 51, 2199, 10.1016/j.jacc.2008.03.016 · DOI · Paper page
- Miettinen, 1989, Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels, Am. J. Clin. Nutr., 49, 629, 10.1093/ajcn/49.4.629 · DOI · Paper page
- Gylling, 1992, Non-cholesterol sterols, absorption and synthesis of cholesterol and apolipoprotein A-I kinetics in a Finnish lecithin-cholesterol acyltransferase deficient family, Atherosclerosis., 95, 25, 10.1016/0021-9150(92)90172-D · DOI
- Beher, 1983, Effect of blood high density lipoprotein cholesterol concentration on fecal steroid excretion in humans, Life Sci., 32, 2933, 10.1016/0024-3205(83)90643-4 · doi:10.1016/0024-3205(83)90643-4
- El-Harchaoui, 2009, Reduced fecal sterol excretion in subjects with familial hypoalphalipoproteinemia, Atherosclerosis., 207, 614, 10.1016/j.atherosclerosis.2009.06.022 · DOI
- Eriksson, 1999, Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans, Circulation., 100, 594, 10.1161/01.CIR.100.6.594 · DOI · Paper page
- Nanjee, 2001, Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans, J. Lipid Res., 42, 1586, 10.1016/S0022-2275(20)32212-4 · DOI
- Brousseau, 2005, Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion, Arterioscler. Thromb. Vasc. Biol., 25, 1057, 10.1161/01.ATV.0000161928.16334.dd · DOI · Paper page
- Schwartz, 1978, Multicompartmental analysis of cholesterol metabolism in man. Characterization of the hepatic bile acid and biliary cholesterol precursor sites, J. Clin. Invest., 61, 408, 10.1172/JCI108952 · DOI · Paper page
- Turner, 2005, Emerging applications of kinetic biomarkers in preclinical and clinical drug development, Curr. Opin. Drug Discov. Devel., 8, 115
- Yvan-Charvet, 2007, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL, Arterioscler. Thromb. Vasc. Biol., 27, 1132, 10.1161/ATVBAHA.106.138347 · DOI · Paper page
- Chirinos, 2005, Ability of serum to decrease cellular acylcoA:cholesterol acyl transferase activity predicts cardiovascular outcomes, Circulation., 112, 2446, 10.1161/CIRCULATIONAHA.104.521815 · DOI
- Oram, 2000, ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages, J. Biol. Chem., 275, 34508, 10.1074/jbc.M006738200 · DOI · Paper page
- Wang, 2004, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins, Proc. Natl. Acad. Sci. USA., 101, 9774, 10.1073/pnas.0403506101 · DOI · Paper page
- Pagler, 2006, SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux, J. Biol. Chem., 281, 11193, 10.1074/jbc.M510261200 · DOI · Paper page
- Pirillo, 2006, 15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages, Biochim. Biophys. Acta., 1761, 292, 10.1016/j.bbalip.2006.03.009 · DOI
- Stangl, 1998, Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoproteins, low density lipoproteins, and nonlipoprotein cholesterol, J. Biol. Chem., 273, 31002, 10.1074/jbc.273.47.31002 · DOI
- Ji, 1997, Scavenger Receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux, J. Biol. Chem., 272, 20982, 10.1074/jbc.272.34.20982 · DOI · Paper page
- Wang, 2007, Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo, J. Clin. Invest., 117, 2216, 10.1172/JCI32057 · DOI · Paper page
- van Dam, 2002, Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study, Lancet., 359, 37, 10.1016/S0140-6736(02)07277-X · DOI · Paper page
- Linsel-Nitschke, 2009, Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in patients undergoing coronary angiography, Lipids Health Dis., 8, 14, 10.1186/1476-511X-8-14 · DOI
- Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler. Thromb. Vasc. Biol., 15, 1987, 10.1161/01.ATV.15.11.1987 · DOI · Paper page
- Navab, 1991, Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein, J. Clin. Invest., 88, 2039, 10.1172/JCI115532 · DOI · Paper page
- Moudry, 1997, Reconstituted high density lipoprotein modulates adherence of polymorphonuclear leukocytes to human endothelial cells, Shock., 7, 175, 10.1097/00024382-199703000-00004 · DOI
- Navab, 2001, HDL and the inflammatory response induced by LDL-derived oxidized phospholipids, Arterioscler. Thromb. Vasc. Biol., 21, 481, 10.1161/01.ATV.21.4.481 · DOI · Paper page
- Lee, 2005, High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity, Atherosclerosis., 183, 251, 10.1016/j.atherosclerosis.2005.03.029 · DOI
- Robbesyn, F, Garcia, V, Auge, N, Vieira, O, Frisach, MF, Salvayre, R, Negre-Salvayre, A. 2003. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-κB activation in smooth muscle cells. FASEB J. 02–0240fje. · DOI
- Puranik, 2008, Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo, Atherosclerosis., 196, 240, 10.1016/j.atherosclerosis.2007.05.008 · DOI
- Nicholls, 2005, Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits, Circulation., 111, 1543, 10.1161/01.CIR.0000159351.95399.50 · DOI · Paper page
- Ansell, 2003, Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment, Circulation., 108, 2751, 10.1161/01.CIR.0000103624.14436.4B · DOI · Paper page
- Navab, 2001, A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids, J. Lipid Res., 42, 1308, 10.1016/S0022-2275(20)31582-0 · DOI · Paper page
- Davies, 1986, Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro, Proc. Natl. Acad. Sci. USA., 83, 2114, 10.1073/pnas.83.7.2114 · DOI · Paper page
- Suc, 1997, HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL, Arterioscler. Thromb. Vasc. Biol., 17, 2158, 10.1161/01.ATV.17.10.2158 · DOI · Paper page
- Sugano, 2000, High-density lipoproteins protect endothelial cells from tumor necrosis factor-[alpha]-induced apoptosis, Biochem. Biophys. Res. Commun., 272, 872, 10.1006/bbrc.2000.2877 · DOI · Paper page
- Nofer, 2001, Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids, J. Biol. Chem., 276, 34480, 10.1074/jbc.M103782200 · DOI · Paper page
- Kimura, 2001, Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells, J. Biol. Chem., 276, 31780, 10.1074/jbc.M104353200 · DOI · Paper page
- Kimura, 2003, High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and Its receptors, Arterioscler. Thromb. Vasc. Biol., 23, 1283, 10.1161/01.ATV.0000079011.67194.5A · DOI · Paper page
- Chen, 1994, Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets, Life Sci., 55, 1815, 10.1016/0024-3205(94)90092-2 · DOI
- Nofer, 2002, HDL and arteriosclerosis: beyond reverse cholesterol transport, Atherosclerosis., 161, 1, 10.1016/S0021-9150(01)00651-7 · DOI · Paper page
- Griffin, 1999, High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C, J. Clin. Invest., 103, 219, 10.1172/JCI5006 · DOI · Paper page
- Oslakovic, 2009, Anionic phospholipids lose their procoagulant properties when incorporated into high- density lipoproteins, J. Biol. Chem., 284, 5896, 10.1074/jbc.M807286200 · DOI
- Deguchi, 2005, High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men, Circulation., 112, 893, 10.1161/CIRCULATIONAHA.104.521344 · DOI · Paper page
- Pomp, 2007, Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations, Br. J. Haematol., 139, 289, 10.1111/j.1365-2141.2007.06780.x · DOI · Paper page
- Alessi, 2008, Metabolic syndrome, haemostasis and thrombosis, Thromb. Haemost., 99, 995, 10.1160/TH07-11-0682 · DOI · Paper page
- Yuhanna, 2001, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat. Med., 7, 853, 10.1038/89986 · DOI · Paper page
- Nieuwdorp, 2008, Reconstituted HDL infusion restores endothelial function in patients with type 2 diabetes mellitus, Diabetologia., 51, 1081, 10.1007/s00125-008-0975-2 · DOI
- Spieker, 2002, High-density lipoprotein restores endothelial function in hypercholesterolemic men, Circulation., 105, 1399, 10.1161/01.CIR.0000013424.28206.8F · DOI · Paper page
- Bisoendial, 2003, Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein, Circulation., 107, 2944, 10.1161/01.CIR.0000070934.69310.1A · DOI · Paper page
- Russell, 2006, Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis, Cardiovasc. Pathol., 15, 318, 10.1016/j.carpath.2006.09.001 · DOI · Paper page
- Lusis, 2007, The problem of passenger genes in transgenic mice, Arterioscler. Thromb. Vasc. Biol., 27, 2100, 10.1161/ATVBAHA.107.147918 · DOI
- Lichtman, 1999, Hyperlipidemia and atherosclerotic lesion development in LDL receptor-deficient mice fed defined semipurified diets with and without cholate, Arterioscler. Thromb. Vasc. Biol., 19, 1938, 10.1161/01.ATV.19.8.1938 · DOI · Paper page
- Plump, 1999, Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 · DOI · Paper page
- Westerterp, 2006, Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice, Arterioscler. Thromb. Vasc. Biol., 26, 2552, 10.1161/01.ATV.0000243925.65265.3c · DOI · Paper page
- Li, 1993, Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice, Arterioscler. Thromb., 13, 1814, 10.1161/01.ATV.13.12.1814 · DOI · Paper page
- Voyiaziakis, 1998, ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice, J. Lipid Res., 39, 313, 10.1016/S0022-2275(20)33893-1 · DOI
- Moore, 2003, Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor, Arterioscler. Thromb. Vasc. Biol., 23, 1914, 10.1161/01.ATV.0000092328.66882.F5 · DOI
- Moore, 2005, Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation, Circ. Res., 97, 763, 10.1161/01.RES.0000185320.82962.F7 · DOI · Paper page
- Nakamuta, 1998, Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: role of apoB mRNA editing in lipoprotein phenotype expression, Arterioscler. Thromb. Vasc. Biol., 18, 747, 10.1161/01.ATV.18.5.747 · DOI
- Rubin, 1991, Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature., 353, 265, 10.1038/353265a0 · DOI · Paper page
- Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse, Proc. Natl. Acad. Sci. USA., 91, 9607, 10.1073/pnas.91.20.9607 · DOI · Paper page
- Paszty, 1994, Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice, J. Clin. Invest., 94, 899, 10.1172/JCI117412 · DOI · Paper page
- Liu, 1994, Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice, J. Lipid Res., 35, 2263, 10.1016/S0022-2275(20)39932-6 · DOI
- Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in Mice, Circulation., 100, 1816, 10.1161/01.CIR.100.17.1816 · DOI · Paper page
- Benoit, 1999, Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models, Circulation., 99, 105, 10.1161/01.CIR.99.1.105 · DOI
- Belalcazar, 2003, Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia, Circulation., 107, 2726, 10.1161/01.CIR.0000066913.69844.B2 · DOI
- Lebherz, 2007, Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent, Cardiovasc. Diabetol., 6, 15, 10.1186/1475-2840-6-15 · DOI
- Miyazaki, 1995, Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits, Arterioscler. Thromb. Vasc. Biol., 15, 1882, 10.1161/01.ATV.15.11.1882 · DOI · Paper page
- Duverger, 1996, Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits, Circulation., 94, 713, 10.1161/01.CIR.94.4.713 · DOI · Paper page
- Wang, 2003, Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux, Arterioscler. Thromb. Vasc. Biol., 23, 1178, 10.1161/01.ATV.0000075912.83860.26 · DOI · Paper page
- Kennedy, 2005, ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation, Cell Metab., 1, 121, 10.1016/j.cmet.2005.01.002 · DOI · Paper page
- Out, 2008, Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1, Circ. Res., 102, 113, 10.1161/CIRCRESAHA.107.161711 · DOI · Paper page
- Joyce, 2006, ABCA1 overexpression in the liver of LDLr-KO mice leads to accumulation of pro-atherogenic lipoproteins and enhanced atherosclerosis, J. Biol. Chem., 281, 33053, 10.1074/jbc.M604526200 · DOI · Paper page
- Joyce, 2002, The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice, Proc. Natl. Acad. Sci. USA., 99, 407, 10.1073/pnas.012587699 · DOI · Paper page
- Basso, 2006, Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet, Biochem. Biophys. Res. Commun., 351, 398, 10.1016/j.bbrc.2006.10.044 · DOI
- Burgess, 2008, Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol., 28, 1731, 10.1161/ATVBAHA.108.168542 · DOI
- Van Eck, 2006, Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice, Arterioscler. Thromb. Vasc. Biol., 26, 929, 10.1161/01.ATV.0000208364.22732.16 · DOI · Paper page
- Curtiss, 2006, Is two out of three enough for ABCG1?, Arterioscler. Thromb. Vasc. Biol., 26, 2175, 10.1161/01.ATV.0000243741.89303.27 · doi:10.1161/01.atv.0000243741.89303.27
- Jonas, 2000, Lecithin cholesterol acyltransferase, Biochim. Biophys. Acta., 1529, 245, 10.1016/S1388-1981(00)00153-0 · DOI · Paper page
- Lambert, 2001, Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice, J. Biol. Chem., 276, 15090, 10.1074/jbc.M008466200 · DOI
- Furbee, 2002, Lecithin:cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice, J. Biol. Chem., 277, 3511, 10.1074/jbc.M109883200 · DOI
- Mertens, 2003, Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis, Circulation., 107, 1640, 10.1161/01.CIR.0000056523.08033.9F · DOI · Paper page
- Berard, 1997, High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithinchoesteryl acyltransferase, Nat. Med., 3, 744, 10.1038/nm0797-744 · DOI · Paper page
- Foger, 1999, Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice, J. Biol. Chem., 274, 36912, 10.1074/jbc.274.52.36912 · DOI · Paper page
- Mehlum, 1997, Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis, APMIS., 105, 861, 10.1111/j.1699-0463.1997.tb05095.x · DOI
- Mehlum, 2000, Overexpression of human lecithin:cholesterol acyltransferase in mice offers no protection against diet-induced atherosclerosis, APMIS., 108, 336, 10.1034/j.1600-0463.2000.d01-65.x · DOI
- Furbee, 2002, Transgenic overexpression of human lecithin: cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition, Atherosclerosis., 165, 89, 10.1016/S0021-9150(02)00201-0 · DOI
- Hoeg, 1996, Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis, Proc. Natl. Acad. Sci. USA., 93, 11448, 10.1073/pnas.93.21.11448 · DOI · Paper page
- Brousseau, 1997, Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner, J. Lipid Res., 38, 2537, 10.1016/S0022-2275(20)30038-9 · DOI
- Brousseau, 2000, LCAT modulates atherogenic plasma lipoproteins and the extent of atherosclerosis only in the presence of normal LDL receptors in transgenic rabbits, Arterioscler. Thromb. Vasc. Biol., 20, 450, 10.1161/01.ATV.20.2.450 · DOI
- Marotti, 1993, Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein, Nature., 364, 73, 10.1038/364073a0 · DOI · Paper page
- Plump, 1999, Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression, Arterioscler. Thromb. Vasc. Biol., 19, 1105, 10.1161/01.ATV.19.4.1105 · DOI · Paper page
- de Haan, 2008, Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin, Circulation., 117, 2515, 10.1161/CIRCULATIONAHA.107.761965 · DOI
- Herrera, 1999, Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein, Nat. Med., 5, 1383, 10.1038/70956 · DOI
- Hayek, 1995, Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene, J. Clin. Invest., 96, 2071, 10.1172/JCI118255 · DOI · Paper page
- Harder, 2007, Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice, Arterioscler. Thromb. Vasc. Biol., 27, 858, 10.1161/01.ATV.0000259357.42089.dc · DOI
- Huang, 2002, Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia, Clin. Sci. (Lond.)., 103, 587, 10.1042/cs1030587 · DOI
- Okamoto, 2000, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, Nature., 406, 203, 10.1038/35018119 · DOI · Paper page
- Rittershaus, 2000, Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 20, 2106, 10.1161/01.ATV.20.9.2106 · DOI · Paper page
- Sugano, 1998, Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits, J. Biol. Chem., 273, 5033, 10.1074/jbc.273.9.5033 · DOI · Paper page
- Morehouse, 2007, Inhibition of CETP activity by torcetrapib reduces susceptibility to diet- induced atherosclerosis in New Zealand White rabbits, J. Lipid Res., 48, 1263, 10.1194/jlr.M600332-JLR200 · DOI · Paper page
- Acton, 1996, Identification of scavenger receptor SR-BI as a high density lipoprotein receptor, Science., 271, 518, 10.1126/science.271.5248.518 · DOI · Paper page
- Rigotti, 1997, A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism, Proc. Natl. Acad. Sci. USA., 94, 12610, 10.1073/pnas.94.23.12610 · DOI · Paper page
- Braun, 2002, Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice, Circ. Res., 90, 270, 10.1161/hh0302.104462 · DOI · Paper page
- Kozarsky, 2000, Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse, Arterioscler. Thromb. Vasc. Biol., 20, 721, 10.1161/01.ATV.20.3.721 · DOI · Paper page
- Covey, 2003, Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells, Arterioscler. Thromb. Vasc. Biol., 23, 1589, 10.1161/01.ATV.0000083343.19940.A0 · DOI · Paper page
- van Eck, 2004, Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development, Am. J. Pathol., 165, 785, 10.1016/S0002-9440(10)63341-X · DOI · Paper page
- McCoy, 2002, Characterization of the lipolytic activity of endothelial lipase, J. Lipid Res., 43, 921, 10.1016/S0022-2275(20)30466-1 · DOI · Paper page
- Ehnholm, 1975, Purification from human plasma of a heparin-released lipase with activity against triglyceride and phospholipids, J. Biol. Chem., 250, 6756, 10.1016/S0021-9258(19)40996-4 · DOI · Paper page
- Busch, 1994, Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice, J. Biol. Chem., 269, 16376, 10.1016/S0021-9258(17)34018-8 · DOI
- Dichek, 2004, Divergent effects of the catalytic and bridging functions of hepatic lipase on atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 24, 1696, 10.1161/01.ATV.0000135981.61827.9d · DOI
- Freeman, 2007, Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice, J. Lipid Res., 48, 104, 10.1194/jlr.M600321-JLR200 · DOI
- Gonzalez-Navarro, 2004, The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice, J. Biol. Chem., 279, 45312, 10.1074/jbc.M406495200 · DOI
- Barcat, 2006, Combined hyperlipidemia/hyperalphalipoproteinemia associated with premature spontaneous atherosclerosis in mice lacking hepatic lipase and low density lipoprotein receptor, Atherosclerosis., 188, 347, 10.1016/j.atherosclerosis.2005.11.022 · DOI
- Ishida, 2004, Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice, J. Biol. Chem., 279, 45085, 10.1074/jbc.M406360200 · DOI
- Ko, 2005, Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE−/− and LDLR−/− mice, J. Lipid Res., 46, 2586, 10.1194/jlr.M500366-JLR200 · DOI
- Tall, 2002, Regulation and mechanisms of macrophage cholesterol efflux, J. Clin. Invest., 110, 899, 10.1172/JCI0216391 · DOI · Paper page
- Schuster, 2002, Accumulation of foam cells in liver X receptor-deficient mice, Circulation., 106, 1147, 10.1161/01.CIR.0000026802.79202.96 · DOI · Paper page
- Joseph, 2002, Synthetic LXR ligand inhibits the development of atherosclerosis in mice, Proc. Natl. Acad. Sci. USA., 99, 7604, 10.1073/pnas.112059299 · DOI · Paper page
- Levin, 2005, Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists, Arterioscler. Thromb. Vasc. Biol., 25, 135, 10.1161/01.ATV.0000150044.84012.68 · DOI · Paper page
- Tangirala, 2002, Identification of macrophage liver X receptors as inhibitors of atherosclerosis, Proc. Natl. Acad. Sci. USA., 99, 11896, 10.1073/pnas.182199799 · DOI · Paper page
- Schultz, 2000, Role of LXRs in control of lipogenesis, Genes Dev., 14, 2831, 10.1101/gad.850400 · DOI · Paper page
- Grefhorst, 2002, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles, J. Biol. Chem., 277, 34182, 10.1074/jbc.M204887200 · DOI · Paper page
- Davies, 2008, Effects of the synthetic liver X receptor agonist T0901317 on the growth hormone and thyroid hormone axes in male rats, Endocrine., 33, 196, 10.1007/s12020-008-9067-9 · DOI
- Schaefer, 1980, Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease), Ann. Intern. Med., 93, 261, 10.7326/0003-4819-93-2-261 · DOI · Paper page
- Clee, 2000, Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes, J. Clin. Invest., 106, 1263, 10.1172/JCI10727 · DOI · Paper page
- Hovingh, 2005, Compromised LCAT function is associated with increased atherosclerosis, Circulation., 112, 879, 10.1161/CIRCULATIONAHA.105.540427 · DOI · Paper page
- Hovingh, 2004, A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease, J. Am. Coll. Cardiol., 44, 1429, 10.1016/j.jacc.2004.06.070 · DOI
- Karathanasis, 1983, An inherited polymorphism in the human apolipoprotein A-I gene locus related to the development of atherosclerosis, Nature., 301, 718, 10.1038/301718a0 · DOI
- Miller, 2007, Do mutations causing low HDL-C promote increased carotid intima-media thickness?, Clin. Chim. Acta., 377, 273, 10.1016/j.cca.2006.10.001 · DOI
- Hong, 2002, Lack of association between increased carotid intima-media thickening and decreased HDL-cholesterol in a family with a novel ABCA1 variant, G2265T, Clin. Chem., 48, 2066, 10.1093/clinchem/48.11.2066 · DOI
- Chiesa, 2003, Apolipoprotein A-I(Milano): current perspectives, Curr. Opin. Lipidol., 14, 159, 10.1097/00041433-200304000-00007 · DOI
- Weibel, 2007, Wild-type apoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux, Arterioscler. Thromb. Vasc. Biol., 27, 2022, 10.1161/ATVBAHA.107.148403 · DOI
- Sirtori, 2008, Viability of developing CETP inhibitors, Cardiovasc. Ther., 26, 135, 10.1111/j.1527-3466.2008.00049.x · DOI
- Klos, 2007, Genetic determinants of HDL: monogenic disorders and contributions to variation, Curr. Opin. Cardiol., 22, 344, 10.1097/HCO.0b013e3281a8acad · DOI
- Edmondson, 2009, Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans, J. Clin. Invest., 119, 1042
- Frikke-Schmidt, 2008, Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease, JAMA., 299, 2524, 10.1001/jama.299.21.2524 · DOI · Paper page
- Johannsen, 2009, Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease, J. Clin. Endocrinol. Metab., 94, 1264, 10.1210/jc.2008-1342 · DOI
- Thompson, 2008, Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk, JAMA., 299, 2777, 10.1001/jama.299.23.2777 · DOI · Paper page
- Robins, 2001, Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial, JAMA., 285, 1585, 10.1001/jama.285.12.1585 · DOI · Paper page
- Saha, 2007, The role of fibrates in the prevention of cardiovascular disease–a pooled meta-analysis of long-term randomized placebo-controlled clinical trials, Am. Heart J., 154, 943, 10.1016/j.ahj.2007.07.011 · DOI
- Kamanna, 2008, Nicotinic acid: recent developments, Curr. Opin. Cardiol., 23, 393, 10.1097/HCO.0b013e3283021c82 · DOI
- van der Hoorn, 2008, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice, Arterioscler. Thromb. Vasc. Biol., 28, 2016, 10.1161/ATVBAHA.108.171363 · DOI · Paper page
- Taylor, 2004, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation., 110, 3512, 10.1161/01.CIR.0000148955.19792.8D · DOI · Paper page
- Taylor, 2006, The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3, Curr. Med. Res. Opin., 22, 2243, 10.1185/030079906X148508 · DOI · Paper page
- Taylor, 2009, Extended-release niacin or ezetimibe and carotid intima-media thickness, N. Engl. J. Med., 361, 2113, 10.1056/NEJMoa0907569 · DOI · Paper page
- Rader, 2003, High-density lipoproteins as an emerging therapeutic target for atherosclerosis, JAMA., 290, 2322, 10.1001/jama.290.17.2322 · DOI
- Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA., 297, 1675, 10.1001/jama.297.15.jpc70004 · DOI · Paper page
- Tall, 2007, CETP inhibitors to increase HDL cholesterol levels, N. Engl. J. Med., 356, 1364, 10.1056/NEJMe078029 · DOI
- de Grooth, 2002, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study, Circulation., 105, 2159, 10.1161/01.CIR.0000015857.31889.7B · DOI · Paper page
- Krishna, 2007, Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies, Lancet., 370, 1907, 10.1016/S0140-6736(07)61813-3 · DOI · Paper page
- Bots, 2007, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial, Lancet., 370, 153, 10.1016/S0140-6736(07)61088-5 · DOI · Paper page
- Kastelein, 2007, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia, N. Engl. J. Med., 356, 1620, 10.1056/NEJMoa071359 · DOI · Paper page
- Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis, N. Engl. J. Med., 356, 1304, 10.1056/NEJMoa070635 · DOI · Paper page
- Vergeer, 2008, Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials, Circulation., 118, 2515, 10.1161/CIRCULATIONAHA.108.772665 · DOI
- Vergeer, 2009, The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors, Am. J. Cardiol., 104, 32E, 10.1016/j.amjcard.2009.09.017 · DOI
- Forrest, 2008, Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone, Br. J. Pharmacol., 154, 1465, 10.1038/bjp.2008.229 · DOI · Paper page
- Navab, 2005, Apolipoprotein A-I mimetic peptides, Arterioscler. Thromb. Vasc. Biol., 25, 1325, 10.1161/01.ATV.0000165694.39518.95 · DOI · Paper page
- Bloedon, 2008, Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients, J. Lipid Res., 49, 1344, 10.1194/jlr.P800003-JLR200 · DOI · Paper page
- Navab, 2008, Apo A-1 mimetic peptides as atheroprotective agents in murine models, Curr. Drug Targets., 9, 204, 10.2174/138945008783755584 · DOI
- Krimbou, 2007, Abstract 679: oral administration of compound RVX-208 increases serum levels of apoA-I and improves high-density lipoprotein-mediated cholesterol efflux in african green monkeys, Circulation., 116, II
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citationMackey, R. H., Greenland, P., Goff, D. C., Lloyd-Jones, D., Sibley, C. T., & Mora, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.060 · Cited by 363
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Haase, C. L., Tybjærg-Hansen, A., Ali Qayyum, A., Schou, J., Nordestgaard, B. G., & Frikke-Schmidt, R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1846 · Cited by 282
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
Metadata
- Authors
- Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., & Kuivenhoven, J. A.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 51
- Issue
- 8
- Pages
- 2058-2073
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2117622925
- Cited by
- 220
- References
- 25
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 3713 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? https://app.cochat.ai/papers/10.1194/jlr.r001610
- The paper
- Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., & Kuivenhoven, J. A. (2010). The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? Journal of Lipid Research. https://doi.org/10.1194/jlr.r001610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.